Skip to content
CancerIndex

Publication

Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.

Authors not recorded

Nat Med2013PMID 23377281PMC3594483stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (10)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 10

Curated evidence

Evidence citing this paper (8)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
23377281
Run
ING-CIVIC-20260908-000001
Open at source
CuratedShowing 1–8 of 8 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
NT5C2 K359Q3
(prognostic)Acute Lymphoblastic LeukemiaPrognosticBSupports Poor Outcome4accepted
EID667

The K359Q somatic mutation was significantly correlated with early disease recurrence and relapse in 103 T-cell ALL regardless of treatment course. The data was obtained from Berlin Frankfurt Münster … (full text at CIViC)

PMID 23377281 · Tzoneva et al., 2013 · Open in CIViC

civic
Arabinosylguanine + NelarabineSubstitutesT Acute Lymphoblastic LeukemiaCURATED_BROADERPredictiveDDoes Not Support Resistance4accepted
EID636

CCRF-CEM and CUTLL1 T-ALL cell lines expressing NT5C2 mutant proteins (K359Q, R367Q or D407A) observed in relapsed T-ALL patients showed no difference in sensitivity to nelarabine or arabinosylguanine… (full text at CIViC)

PMID 23377281 · Tzoneva et al., 2013 · Open in CIViC

civic
Mercaptopurine + ThioguanineSubstitutesT Acute Lymphoblastic LeukemiaCURATED_BROADERPredictiveDSupports Resistance4accepted
EID631

CCRF-CEM and to a lesser extent CUTLL1 T-ALL cell lines expressing the NT5C2 K359Q mutation had increased resistance to 6-mercaptopurine and 6-thioguanine treatment than cells expressing wildtype NT5C… (full text at CIViC)

PMID 23377281 · Tzoneva et al., 2013 · Open in CIViC

civic
NT5C2 D407A2
Mercaptopurine + ThioguanineSubstitutesT Acute Lymphoblastic LeukemiaCURATED_BROADERPredictiveDSupports Resistance4accepted
EID632

CCRF-CEM and to a lesser extent CUTLL1 T-ALL cell lines expressing the NT5C2 D407A mutation had increased resistance to 6-mercaptopurine and 6-thioguanine treatment than cells expressing wildtype NT5C… (full text at CIViC)

PMID 23377281 · Tzoneva et al., 2013 · Open in CIViC

civic
Arabinosylguanine + NelarabineSubstitutesT Acute Lymphoblastic LeukemiaCURATED_BROADERPredictiveDDoes Not Support Resistance4accepted
EID635

CCRF-CEM and CUTLL1 T-ALL cell lines expressing NT5C2 mutant proteins (K359Q, R367Q or D407A) observed in relapsed T-ALL patients showed no difference in sensitivity to nelarabine or arabinosylguanine… (full text at CIViC)

PMID 23377281 · Tzoneva et al., 2013 · Open in CIViC

civic
NT5C2 R367Q3
Mercaptopurine + ThioguanineSubstitutesT Acute Lymphoblastic LeukemiaCURATED_BROADERPredictiveDSupports Resistance4accepted
EID630

CCRF-CEM and to a lesser extent CUTLL1 T-ALL cell lines expressing the NT5C2 R367Q mutation had increased resistance to 6-mercaptopurine and 6-thioguanine treatment than cells expressing wildtype NT5C… (full text at CIViC)

PMID 23377281 · Tzoneva et al., 2013 · Open in CIViC

civic
Arabinosylguanine + NelarabineSubstitutesT Acute Lymphoblastic LeukemiaCURATED_BROADERPredictiveCSupports Sensitivity Response4rejected
EID634

CCRF-CEM and CUTLL1 T-ALL cell lines expressing NT5C2 mutant proteins (R367Q, R359Q or D407A) observed in relapsed T-ALL patients showed no difference in sensitivity to nelarabine or arabinosylguanine… (full text at CIViC)

PMID 23377281 · Tzoneva et al., 2013 · Open in CIViC

civic
〃T Acute Lymphoblastic LeukemiaCURATED_BROADERPredictiveDDoes Not Support Resistance4accepted
EID633

CCRF-CEM and CUTLL1 T-ALL cell lines expressing NT5C2 mutant proteins (K359Q, R367Q or D407A) observed in relapsed T-ALL patients showed no difference in sensitivity to nelarabine or arabinosylguanine… (full text at CIViC)

PMID 23377281 · Tzoneva et al., 2013 · Open in CIViC

civic